Search
forLearn
5 / 801 resultslearn Synergen Complex ®
learn oligopeptide-71
learn Beta glucan
learn myristoyl pentapeptide-17
Research
5 / 1000+ resultsresearch Features of sensitization in patients with alopecia areata, associated with atopic diseases
Alopecia areata often occurs with atopic diseases, especially in children.
research Mechanisms of proton inhibition and sensitization of the cation channel TRPV3
Acid can block TRPV3 from outside the cell but boost its function from inside.
research 032 A multicomponent skin-targeted COVID-19 vaccine elicits robust humoral and cellular immune responses
The new skin-targeted COVID-19 vaccine creates strong immune responses and could improve vaccination methods.
research Improved humoral immunity and protection against influenza virus infection with a 3D porous biomaterial vaccine
The new vaccine platform led to a stronger immune response and better protection against the flu than the traditional vaccine.
research Enhancement of Immune Responses Elicited by Nanovaccines through a Cross-Presentation Pathway
Community Join
5 / 1000+ resultscommunity Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community Trial for TDM-105795 update from research office
The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.
community PP405 2a study was a safety study. Some rational explaining.
The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.
community PG causing irritation when applying RU
The user is experiencing irritation from using PG with RU58841 and is seeking alternative solutions like K&B in the UK. They report redness, itchiness, and flaky skin from the current treatment.
community Update for PP405 - phase 2b underway
PP405 is advancing to Phase 2b trials, showing promise from Phase 2a. It may be available in 3-6 years, with trials using a topical gel.